HOW THIS WORKS: most trials in our database only care about some (not all) of the questions. When you answer a question, we look to see which trials in our database consider that question relevant. If your answer matches what any of those trials are looking for, we increase those trials' "relevance" scores by 1 in the table of results. If your answer doesn't match what a trial is looking for, then that trial will not be displayed. The best way to narrow down the results below is by answering all of the questions.
TRIAL DATA LAST UPDATED: 2025-01-16 17:38:09
TRIAL DATA LAST UPDATED: 2025-01-16 17:38:09
Matching Clinical Trials(no questions answered yet)
| Description | Location(s) | Relevance |
|---|---|---|
|
Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
read more
The purpose of this study is to determine whether accelerated BEP chemotherapy is more effective than standard BEP chemotherapy in males with intermediate and poor-risk metastatic germ cell tumors (including testicular cancer).
Bleomycin, Etoposide, Cisplatin (BEP) remains standard first line chemotherapy for intermediate- and poor-risk metastatic germ cell tumours (GCTs). Cure rates are over 90% for good-risk disease, 85% with intermediate-risk, and about 70% for poor-risk disease.
Previous strategies to improve first-line chemotherapy have failed to improve cure rates and were more toxic than BEP. New strategies are needed for patients with intermediate and poor-risk disease. BEP is accelerated by cycling Cisplatin and etoposide. The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) is conducting this trial comparing accelerated BEP with standard BEP.
|
GUH | 0 |
|
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
read more
This phase III trial studies how well active surveillance, bleomycin, carboplatin, etoposide, or cisplatin (all types of chemotherapy) work in treating pediatric and adult patients with germ cell tumors (including testicular cancer).
Active surveillance may help doctors to monitor subjects with low risk germ cell tumors after their tumor is removed.
Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
|
GUH | 0 |
|
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
read more
This research trial studies the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.
Patients undergo medical data review to create a Childhood Cancer Registry. Patients also undergo collection of bio-specimen samples (e.g., tissue, blood, bone marrow, plasma, serum, buccal cells, saliva, cerebrospinal fluid, or urine).
This is NOT a treatment study.
|
GUH | 0 |
|
First-in-human, Open-label, Multicenter, Phase I/IIa, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT142 in Patients With CLDN6-positive Advanced Solid Tumors
read more
This study is an open-label, multicenter, Phase I/IIa, dose escalation, safety, and pharmacokinetics (PK) study of BNT142 (a type of immunotherapy) followed by expansion cohorts in patients with Claudin 6 (CLDN6)-positive advanced tumors. The expansion cohorts include advanced/metastatic ovarian cancer, non-small cell lung cancer (NSCLC) of non-squamous type, and testicular cancer patients who have progressed on or after last prior treatment.
All patients will receive treatment with BNT142 given as an intravenous (IV) infusion. Dose level and dosing schedule will be provided by the treatment site.
|
UMD | 0 |
